This finding is consistent with several studies that reported a reduction in the incidence rate of T2D among patients with rheumatic diseases and using other cDMARDs including hydroxychloroquine (HCQ) [44] and TNF inhibitors (TNFi) [45]. The gene discussed is TNF; the disease is type 2 diabetes mellitus.